Trump announces 100% chip tariff as Apple ups U.S. investment
SILVER SPRING, Md. - United Therapeutics Corporation (NASDAQ:UTHR) reported first quarter 2025 financial results that exceeded analyst expectations on Wednesday.
The company’s shares were up 0.74% in early trading.
The biopharmaceutical company posted adjusted earnings per share of $6.63, beating the consensus estimate of $6.53. Revenue for the quarter came in at $794.4 million, surpassing analyst projections of $728.34 million and representing a 17% increase YoY from $677.7 million in Q1 2024.
Total (EPA:TTEF) Tyvaso revenues, including both the inhaled and dry powder formulations, grew 25% YoY to $466.3 million. Tyvaso DPI sales jumped 33% to $302.5 million, driven by patient growth and increased commercial utilization following Medicare Part D benefit changes.
"2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and CEO of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we’ll progress our innovation and revolution waves of growth."
The company highlighted upcoming milestones, including the readout of its TETON 2 trial in idiopathic pulmonary fibrosis and planned regulatory filings for organ transplant technologies.
United Therapeutics maintained a strong balance sheet, with $5.03 billion in cash and investments as of March 31, 2025.
The company will host a conference call later today to discuss the quarter in more detail.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.